English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

A recent study by Melani et al .[1][1] aimed to determine the value of end-of-treatment FDG-PET and serial follow-up FDG-PET in patients with primary mediastinal B-cell lymphoma (PMBCL) treated with dose-adjusted EPOCH-R. End-of-treatment FDG-PET was performed in 80 patients, 57 of whom received 144

Unproven value of end-of-treatment and serial follow-up FDG-PET in primary mediastinal B-cell lymphoma